February 13, 2014

GlobeImmune, Inc., today announced that on February 11, 2014, the company completed a $7.5 million private placement of convertible notes and warrants. Continue reading

October 15, 2013

GlobeImmune Announces Milestone Payment for Initiation of Phase 2 Clinical Trial for GS-4774 (Formerly GI-13020) Continue reading

September 04, 2013

April 18, 2013

GlobeImmune, Inc., today announced that Timothy C. Rodell, M.D. will present at the 12th Annual Needham Healthcare Conference on Tuesday, April 30, 2013 in New York. Continue reading

April 03, 2013

GlobeImmune, Inc., announced today the initiation of a Phase 2 clinical trial at the National Cancer Institute (NCI) to evaluate GI-6207 in subjects with medullary thyroid cancer (MTC). Continue reading

January 28, 2013

November 11, 2012

November 10, 2012

July 02, 2012